Jaguar Health Inc. (NASDAQ: JAGX) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT JAGUAR HEALTH INC.

Jaguar Health Inc. (NASDAQ: JAGX)
Listen to this Section


$2.33
-0.1450 ( -5.87% ) 31.0K

Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.

Clinical Trial Pipeline Stages


Drug Name Stage
Canalevia (crofelemer)DetailsNoninfectious diarrhea Approved
CrofelemerDetailsNoninfectious diarrhea, Chemotherapy induced nausea and vomiting Phase 3
Crofelemer powderDetailsMicrovillus inclusion disease, Short bowel syndrome Phase 2

Market Data


Open $2.33
Previous Close $2.47
Volume 31.0K
Market Cap $1.78M
Day Range $2.28 - $2.60
52 Week Range $2.28 - $113.91
Shares Outstanding 0.72M
Change % -5.87%
Net Change ▼ -0.1450
Insider Ownership -0.01%
Exchange NASDAQ
SectorHealthcare
IndustryBiotechnology: Pharmaceutical Preparations
IPO Year2015
CountryUnited States
UnderwriterIPO Intelligence Only

Insider Ownership Transactions

Total Amount Purchased: -1,307,689.00

Date Type Amount Purchased Purchaser
2024-05-21 Sale -871.00 Chaturvedi Pravin R
2024-05-21 Sale -871.00 Wolin Jonathan S.
2024-05-21 Sale -612.00 King Steven R.
2024-05-21 Sale -431.00 Lizak Carol R.
2024-05-21 Sale -2695.00 CONTE LISA A
2024-04-17 Sale -600.00 CONTE LISA A
2024-04-17 Sale -60.00 Lizak Carol R.
2024-04-17 Sale -134.00 Chaturvedi Pravin R
2024-04-17 Sale -89.00 Wolin Jonathan S.
2024-04-17 Sale -178.00 King Steven R.

SEC Filings


Form Type Description Pages Date
8-k 8K-related 17 Nov 14, 2025
10-q Quarterly Reports 107 Nov 14, 2025
def Proxies and info statements 16 Nov 10, 2025
pre Proxies and info statements 15 Oct 28, 2025
8-k 8K-related 12 Oct 03, 2025
8-k 8K-related 14 Oct 01, 2025
8-k 8K-related 14 Sep 11, 2025
3 Insider transactions 1 Aug 29, 2025
8-k 8K-related 14 Aug 19, 2025
8-k 8K-related 13 Aug 14, 2025

Latest News


× Before browsing our site, please accept our cookies policy